As a general mechanism to keep potentially autoreactive CD8+ T-cell clones under control after AHSCT, PD-1 expression may be a reliable immune marker of clinical response in SSc and MS patients after AHSCT (48) (Table 1). This evidence concerns the gene PDCD1 and systemic sclerosis.